Biocon Biologics proudly celebrated a significant milestone with the official opening of its new North America headquarters in Bridgewater, New Jersey, on Friday, September 13. This occasion also marked the Company’s first-year anniversary in the region, further solidifying its commitment to providing high-quality, affordable biosimilar medicines to patients in North America and across the globe. The Company, based in Bridgewater, is a leading provider of high-quality, affordable biosimilar medicines to treat conditions from cancer to diabetes. It is the fourth largest insulins company in the world, providing over 3.75 billion doses to help patients manage diabetes.
Biocon Biologics Opens North America Headquarters in New Jersey’s Biopharma Corridor
Biocon Biologics recently moved into a 9,624-square-foot (sf) office located at 685 Route 202/206 in Bridgewater within the State’s biopharma corridor where the new headquarters will house both commercial and administrative functions.
The ribbon-cutting event was hosted by the Company’s Chief Commercial Officer for Advanced Markets Matt Erick and Head of North America Josh Salsi, who were joined by Mayor Matt Moench, Township of Bridgewater; New Jersey State Assemblyman Erik Peterson; Gail Feltham, Director of Life Sciences Partnerships, New Jersey Economic Development Authority; Jessica Paolini, Somerset County Economic Development Authority; Chris Allen, Chief of Staff, State Senator Douglas J. Steinhardt; Sara Sooy, Somerset County Commissioner Deputy Director; Colleen Mahr, Somerset County Administrator; Wells Winegar, Deputy Township Administrator, Township of Bridgewater; and Matt Smith, Legislative Aide, NJ State Assemblyman John DiMaio.
Earlier in the day, Congressman Thomas Kean Jr. and Erin Darreff, District Director, also visited the office, presenting Biocon Biologics with a certificate in recognition of its contributions to the community.
“Biocon Biologics is paving the way for a more affordable and accessible future in biopharmaceuticals, driving innovation in biosimilars to improve global healthcare outcomes. I am thrilled to welcome Biocon Biologics to the community and look forward to the groundbreaking advancements and positive impact this company will bring to New Jerseyans, Americans across the country, and people around the world.”
Thomas Kean Jr.
U.S. representative from New Jersey’s 7th congressional district
Bridgewater Mayor Matt Moench emphasized Biocon Biologics’ contribution to the community, “Thank you for choosing Bridgewater and for your dedication to providing real relief for people in need of life-saving medicines.”
Assemblyman Erik Peterson added, “I am thankful Biocon Biologics chose Bridgewater for its North America headquarters. I am proud to have in my legislative district quality companies such as Biocon Biologics with their highly skilled associates who are making a difference in people’s lives. I believe in what Biocon Biologics is doing to deliver quality pharmaceutical products to all Americans. Together, we can change things for the people for the better to ensure that medicines are available not only here in New Jersey, but across the country at a price we can afford and with quality we can rely on.”
“We are excited to establish our first North America headquarters within the hub of the biopharma sector of New Jersey where we can leverage the strong life sciences ecosystem of innovation, talent, and excellent quality of life for our employees and be well-positioned for future growth.”
Joshua Salsi
Head of North America,
Biocon Biologics
A step ahead in our journey of innovation and excellence
Biocon Biologics’ presence in North America is a testament to its 45-year legacy of innovation and scientific excellence. Since its inception in 1978, the Company has evolved from an enzyme manufacturer into a leading global biopharma enterprise, driven by a unique integrated structure that includes in-house development, manufacturing, and commercial capabilities. The integration of the acquired biosimilars business from Viatris has expanded Biocon Biologics into over 120 countries, with a product pipeline of 20 biosimilar molecules and eight commercialized products in global markets. Biocon Biologics also ranks among the top 15 global biomanufacturing capacities, with over 5.5 million patients served worldwide.
As the Company commemorates its first anniversary in North America and officially opens its new headquarters, Biocon Biologics is poised for continued growth and innovation, furthering its mission to enhance patient access to affordable biologics and transform healthcare globally.
